Procollagen‑lysine, 2‑oxoglutarate 5‑dioxygenase 1 increases cellular proliferation and colony formation capacity in lung cancer via activation of E2F transcription factor 1

Li,Baijun; Yang,Hao; Shen,Bin; Huang,Jianwei; Qin,Zhiqiang

doi:10.3892/ol.2021.13112

Procollagen‑lysine, 2‑oxoglutarate 5‑dioxygenase 1 increases cellular proliferation and colony formation capacity in lung cancer via activation of E2F transcription factor 1

Authors:
- Baijun Li
- Hao Yang
- Bin Shen
- Jianwei Huang
- Zhiqiang Qin
View Affiliations

Affiliations: Department of Thoracic Cardiovascular Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, P.R. China, Department of Administration, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, P.R. China, Department of Pulmonary and Critical Care Medicine, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi 530021, P.R. China
Published online on: October 26, 2021 https://doi.org/10.3892/ol.2021.13112
Article Number: 851
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Procollagen‑lysine, 2‑oxoglutarate 5‑dioxygenase 1 (PLOD1) is an enzyme that catalyzes the hydroxylation of lysyl residues in collagen‑like peptides, and is responsible for the stability of intermolecular crosslinks. High PLOD1 mRNA levels have been determined to be prognostically significant in numerous human malignancies. The objective of the present study was to elucidate the pathological mechanism of PLOD1 in lung cancer. The expression status and prognostic value of PLOD1 in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSA) were investigated using Gene Expression Profiling Interactive Analysis (GEPIA). Cell Counting Kit 8 and colony formation assays were performed to assess the impact of PLOD1 depletion and overexpression on the proliferation and colony formation abilities of the A549 lung cancer cell line. Luciferase reporter assays were used to clarify whether E2F transcription factor 1 (E2F1) was a downstream target of PLOD1 in lung cancer. Finally, the correlations between PLOD1 expression and a typical central downstream effector molecule of E2F1 signaling were determined using cBioportal. The GEPIA datasets revealed that PLOD1 mRNA levels were upregulated in LUAD and LUSC samples. Furthermore, the overexpression of PLOD1 promoted cancer cell proliferation and colony formation in vitro, while PLOD1‑knockout produced the opposite effect. Notably, PLOD1 markedly induced the transcriptional activity of E2F1. Additionally, the expression of PLOD1 was significantly correlated with that of H2A histone family member X. In conclusion, the findings of the present study indicate that PLOD1 promoted lung cancer through E2F1 activation, and proposed a rationale for targeting the PLOD1/E2F1 axis to treat lung cancer.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018.Erratum in: CA Cancer J Clin 70: 313. 2020. View Article : Google Scholar : PubMed/NCBI
2	International Agency for Research on Cancer (IARC), . World Cancer Report: Cancer Research for Cancer Prevention. Wild CP, Weiderpass E and Stewart BW: IARC; Lyon: 2020
3	Koudelakova V, Kneblova M, Trojanec R, Drabek J and Hajduch M: Non-small cell lung cancer - genetic predictors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 157:125–136. 2013. View Article : Google Scholar : PubMed/NCBI
4	Clausen MM and Langer SW: Improving the prognosis for lung cancer patients. Acta Oncol. 58:1077–1078. 2019. View Article : Google Scholar : PubMed/NCBI
5	Woodard GA, Jones KD and Jablons DM: Lung cancer staging and prognosis. Cancer Treat Res. 170:47–75. 2016. View Article : Google Scholar : PubMed/NCBI
6	Qi Y and Xu R: Roles of PLODs in collagen synthesis and cancer progression. Front Cell Dev Biol. 6:662018. View Article : Google Scholar : PubMed/NCBI
7	Eisinger-Mathason TS, Zhang M, Qiu Q, Skuli N, Nakazawa MS, Karakasheva T, Mucaj V, Shay JE, Stangenberg L, Sadri N, et al: Hypoxia-dependent modification of collagen networks promotes sarcoma metastasis. Cancer Discov. 3:1190–1205. 2013. View Article : Google Scholar : PubMed/NCBI
8	Chang WH, Forde D and Lai AG: Dual prognostic role of 2-oxoglutarate-dependent oxygenases in ten cancer types: Implications for cell cycle regulation and cell adhesion maintenance. Cancer Commun (Lond). 39:232019. View Article : Google Scholar : PubMed/NCBI
9	Li SS, Lian YF, Huang YL, Huang YH and Xiao J: Overexpressing PLOD family genes predict poor prognosis in gastric cancer. J Cancer. 11:121–131. 2020. View Article : Google Scholar : PubMed/NCBI
10	Zhang T, Li Y, Zhu R, Song P, Wei Y, Liang T and Xu G: Transcription factor p53 suppresses tumor growth by prompting pyroptosis in non-small-cell lung cancer. Oxid Med Cell Longev. 2019:87468952019. View Article : Google Scholar : PubMed/NCBI
11	Yamada Y, Kato M, Arai T, Sanada H, Uchida A, Misono S, Sakamoto S, Komiya A, Ichikawa T and Seki N: Aberrantly expressed PLOD1 promotes cancer aggressiveness in bladder cancer: A potential prognostic marker and therapeutic target. Mol Oncol. 13:1898–1912. 2019. View Article : Google Scholar : PubMed/NCBI
12	Wu X, Xiang H, Cong W, Yang H, Zhang G, Wang Y, Guo Z, Shen Y and Chen B: PLOD1, a target of miR-34c, contributes to cell growth and metastasis via repressing LATS1 phosphorylation and inactivating Hippo pathway in osteosarcoma. Biochem Biophys Res Commun. 527:29–36. 2020. View Article : Google Scholar : PubMed/NCBI
13	Hollern DP, Honeysett J, Cardiff RD and Andrechek ER: The E2F transcription factors regulate tumor development and metastasis in a mouse model of metastatic breast cancer. Mol Cell Biol. 34:3229–3243. 2014. View Article : Google Scholar : PubMed/NCBI
14	Denechaud PD, Fajas L and Giralt A: E2F1, a novel regulator of metabolism. Front Endocrinol (Lausanne). 8:3112017. View Article : Google Scholar : PubMed/NCBI
15	Malaney P, Palumbo E, Semidey-Hurtado J, Hardee J, Stanford K, Kathiriya JJ, Patel D, Tian Z, Allen-Gipson D and Davé V: PTEN physically interacts with and regulates E2F1-mediated transcription in lung cancer. Cell Cycle. 17:947–962. 2018. View Article : Google Scholar : PubMed/NCBI
16	Sun CC, Zhou Q, Hu W, Li SJ, Zhang F, Chen ZL, Li G, Bi ZY, Bi YY, Gong FY, et al: Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. Aging (Albany NY). 10:973–987. 2018. View Article : Google Scholar : PubMed/NCBI
17	Zhao M, Liu Y, Chang J, Qi J, Liu R, Hou Y, Wang Y, Zhang X, Qiao L and Ren L: ILF2 cooperates with E2F1 to maintain mitochondrial homeostasis and promote small cell lung cancer progression. Cancer Biol Med. 16:771–783. 2019.PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Liu J, Li W, Zhang J, Ma Z, Wu X and Tang L: Identification of key genes and long non-coding RNA associated ceRNA networks in hepatocellular carcinoma. PeerJ. 7:e80212019. View Article : Google Scholar : PubMed/NCBI
20	Folk WP, Kumari A, Iwasaki T, Pyndiah S, Johnson JC, Cassimere EK, Abdulovic-Cui AL and Sakamuro D: Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin. J Biol Chem. 294:5700–5719. 2019. View Article : Google Scholar : PubMed/NCBI
21	Du H, Pang M, Hou X, Yuan S and Sun L: PLOD2 in cancer research. Biomed Pharmacother. 90:670–676. 2017. View Article : Google Scholar : PubMed/NCBI
22	He J, Wei W, Yang Q and Wang Y: Phillygenin exerts in vitro and in vivo antitumor effects in drug-resistant human esophageal cancer cells by inducing mitochondrial-mediated apoptosis, ROS generation, and inhibition of the nuclear factor kappa B NF-κB signalling pathway. Med Sci Monit. 25:739–745. 2019. View Article : Google Scholar : PubMed/NCBI
23	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
24	Wang D, Zhang S and Chen F: High expression of PLOD1 drives tumorigenesis and affects clinical outcome in gastrointestinal carcinoma. Genet Test Mol Biomarkers. 22:366–373. 2018. View Article : Google Scholar : PubMed/NCBI
25	Allan RJ and Roxon JJ: The effect of dioctyl sodium sulphosuccinate on tartrazine azo reduction by intestinal bacteria. Xenobiotica. 7:181–186. 1977. View Article : Google Scholar : PubMed/NCBI
26	Yin J, Fu W, Dai L, Jiang Z, Liao H, Chen W, Pan L and Zhao J: ANKRD22 promotes progression of non-small cell lung cancer through transcriptional up-regulation of E2F1. Sci Rep. 7:44302017. View Article : Google Scholar : PubMed/NCBI
27	Wu B and Liu R: PAQR4 promotes cell proliferation and metastasis through the CDK4-pRB-E2F1 pathway in non-small-cell lung cancer. OncoTargets Ther. 12:3625–3633. 2019. View Article : Google Scholar : PubMed/NCBI
28	Gao S, Song Q, Liu J, Zhang X, Ji X and Wang P: E2F1 mediates the downregulation of POLD1 in replicative senescence. Cell Mol Life Sci. 76:2833–2850. 2019. View Article : Google Scholar : PubMed/NCBI
29	Palomer X, Álvarez-Guardia D, Davidson MM, Chan TO, Feldman AM and Vázquez-Carrera M: The interplay between NF-kappaB and E2F1 coordinately regulates inflammation and metabolism in human cardiac cells. PLoS One. 6:e197242011. View Article : Google Scholar : PubMed/NCBI
30	Mia MM and Bank RA: The IκB kinase inhibitor ACHP strongly attenuates TGFβ1-induced myofibroblast formation and collagen synthesis. J Cell Mol Med. 19:2780–2792. 2015. View Article : Google Scholar : PubMed/NCBI